Efficacy and Safety of Nilotinib Patients With Newly Diagnosed CML - CP (Chronic Myelogenous Leukemia - Chronic Phase) — PHCHBS-WD4070

Myelogenous Leukemia, Chronic Clinical Trial

Official title:
Extension Study to a Phase III Multi-center, Open-label, Randomized Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

Status Active, not recruiting

Clinical Trial Summary

This study will evaluate the safety and tolerability of nilotinib after failure of imatinib therapy or imatinib therapy after nilotinib failure.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Leukemia
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid
Leukemia, Myeloid, Chronic-Phase
Myelogenous Leukemia, Chronic

Clinical Trial Details

NCT number	NCT00718263
Study type	Interventional
Source	Novartis
Contact
Status	Active, not recruiting
Phase	Phase 3
Start date	April 2008
Completion date	October 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02736721` - Expanded Access Study With Peginterferon Alfa-2a (Pegasys) in Participants With Chronic Myelogenous Leukemia (CML)	Phase 3
Completed	`NCT00179764` - Immunoablative Mini Transplant (Hematopoietic Peripheral Blood Stem Cell Transplant [HPBSC])	N/A
Completed	`NCT00111683` - MK0457 in Patients With Leukemia (0457-003)	Phase 1
Completed	`NCT00471497` - A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)	Phase 3
Active, not recruiting	`NCT01503502` - A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous Leukemia	Phase 2
Completed	`NCT00038597` - Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML)	Phase 2